Wegovy vs Mounjaro - Compare Cheapest UK Prices

Our Pricing

Wegovy vs Mounjaro: Which Weight Loss Injection Works Best?

When comparing Wegovy vs Mounjaro, both represent the most effective prescription weight loss injections available in the UK, yet they work through different mechanisms and deliver distinct results. As a UK pharmacist who has guided thousands of patients through weight management journeys, I've seen how understanding the clinical differences between semaglutide (Wegovy) and tirzepatide (Mounjaro) helps patients make informed decisions with their prescriber. This comprehensive comparison examines trial data, real-world efficacy, side effect profiles, and UK pricing to help you understand which treatment may suit your individual circumstances.

How Wegovy vs Mounjaro Mechanisms Differ Clinically

The fundamental difference when evaluating Wegovy vs Mounjaro lies in their receptor activity. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single gut hormone to regulate appetite and blood sugar [1]. Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously [2].

This dual mechanism gives Mounjaro a theoretical advantage in metabolic impact. In clinical practice at Cured Pharmacy, patients often ask whether this translates to superior weight loss. The SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in type 2 diabetes patients, showing tirzepatide achieved greater HbA1c reduction and weight loss across all dose levels [2]. However, when comparing Wegovy vs Mounjaro specifically for weight loss, we must consider that Wegovy uses the higher 2.4mg semaglutide maintenance dose, whilst Mounjaro escalates to 15mg tirzepatide maximum.

Both medications slow gastric emptying, reduce appetite through hypothalamic pathways, and improve insulin sensitivity. The dual receptor activation of Mounjaro may offer enhanced glucose control and potentially greater fat mass reduction, though individual response varies considerably based on metabolic profile, adherence, and baseline characteristics [1][2].

Wegovy vs Mounjaro Weight Loss Results: Clinical Trial Data

The STEP clinical trial programme for Wegovy demonstrated average weight loss of 15-17% of body weight over 68 weeks in adults without diabetes [1]. Participants on semaglutide 2.4mg lost an average of 15.3kg compared to 2.6kg with placebo in the pivotal STEP 1 trial, with two-thirds achieving at least 10% weight reduction.

Mounjaro's SURMOUNT-1 trial showed even more substantial results, with participants losing an average of 15%, 19.5%, and 22.5% of body weight on the 5mg, 10mg, and 15mg doses respectively over 72 weeks [2]. At the highest dose, average weight loss reached 23.6kg compared to 2.4kg with placebo, making tirzepatide the most effective obesity medication in clinical trials to date.

When directly comparing Wegovy vs Mounjaro efficacy, the higher-dose tirzepatide generally produces 3-7% greater total body weight reduction than semaglutide 2.4mg across pooled trial data [2]. However, in my experience supporting patients at Cured Pharmacy, individual results vary widely. Some patients achieve excellent outcomes on Wegovy at £124.99 without needing to escalate to Mounjaro, whilst others may benefit from tirzepatide's dual mechanism if initial response is suboptimal. Both medications require commitment to dietary modification and increased physical activity for optimal results, and all treatment decisions must be made with your UK prescriber following clinical assessment.

Real-World Effectiveness Beyond Clinical Trials

Whilst controlled trials provide invaluable data, real-world effectiveness often differs due to adherence challenges, dose titration variations, and diverse patient populations. Observational UK data suggests both Wegovy and Mounjaro maintain clinically significant weight loss when patients continue treatment beyond one year, though discontinuation rates range from 30-40% primarily due to gastrointestinal side effects or cost considerations [1][2]. At Cured Pharmacy, we emphasise that sustainable weight management requires long-term commitment, and the 'best' medication is the one you can tolerate and afford consistently.

Side Effects Profile: Wegovy vs Mounjaro Tolerability

Gastrointestinal side effects dominate the tolerability profile for both medications when comparing Wegovy vs Mounjaro. Nausea, diarrhoea, vomiting, constipation, and abdominal discomfort occur in 30-50% of patients, typically most pronounced during dose escalation phases [1][2].

Wegovy's side effect profile from the STEP trials showed nausea in approximately 44% of participants, diarrhoea in 30%, vomiting in 24%, and constipation in 24% [1]. Most gastrointestinal symptoms were mild to moderate and diminished over 4-8 weeks as patients adapted to each dose level. Serious adverse events were rare, occurring in 9.8% of semaglutide patients versus 6.4% on placebo.

Mounjaro demonstrated similar gastrointestinal side effects in SURMOUNT trials, with nausea affecting 29-38% depending on dose, diarrhoea 23-26%, vomiting 10-12%, and constipation 17-21% [2]. Interestingly, despite higher efficacy, tirzepatide's side effect rates were comparable or slightly lower than semaglutide in head-to-head comparison, possibly due to the GIP component modulating GLP-1-related nausea.

Managing Side Effects in Clinical Practice

When counselling patients at Cured Pharmacy on Wegovy vs Mounjaro tolerability, I recommend slow dose titration, eating smaller meals, avoiding high-fat foods, and staying well-hydrated to minimise gastrointestinal symptoms. Both medications carry theoretical risks of pancreatitis, gallbladder disease, and thyroid C-cell tumours (contraindicated in personal or family history of medullary thyroid carcinoma or MEN2 syndrome), though absolute risk remains very low [1][2]. Regular monitoring by your prescriber ensures early detection of any concerning symptoms, and dose adjustment or medication switching can optimise tolerability whilst maintaining weight loss benefits.

Dosing Schedules: Wegovy vs Mounjaro Titration Protocols

Both medications use gradual dose escalation to improve gastrointestinal tolerability, but their titration schedules differ when comparing Wegovy vs Mounjaro protocols. Wegovy follows a five-month escalation: 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally the 2.4mg maintenance dose [1]. Each dose level lasts four weeks, allowing physiological adaptation before increasing.

Mounjaro uses a faster titration over 12-20 weeks depending on tolerability and efficacy targets. The starting dose is 2.5mg weekly for four weeks, increasing to 5mg, then optionally to 7.5mg, 10mg, 12.5mg, and 15mg maximum [2]. Many patients achieve satisfactory weight loss at 5mg or 10mg without requiring the highest dose, allowing for individualised treatment.

In my experience at Cured Pharmacy, the slower Wegovy titration suits patients particularly sensitive to gastrointestinal side effects, whilst Mounjaro's faster escalation appeals to those seeking more rapid results. When discussing Wegovy vs Mounjaro dosing with your prescriber, consider your previous tolerance to similar medications, urgency of weight loss goals, and willingness to manage potential side effects during the initial months. Both medications are administered via subcutaneous injection once weekly, rotating between abdomen, thigh, or upper arm sites.

Cost Comparison: Wegovy vs Mounjaro UK Pricing

Price represents a significant consideration when evaluating Wegovy vs Mounjaro, as both require long-term use for sustained weight management and are not routinely funded by the NHS for obesity treatment outside specialist services. At Cured Pharmacy, Wegovy is available from £124.99 per month following online clinical assessment by our UK prescribers, with £20 off your first order using code Weightlossnew [3].

Mounjaro pricing starts from £124.99 per month at Cured Pharmacy, reflecting the higher cost of this newer dual-agonist medication [3]. Whilst Mounjaro demonstrates superior average weight loss in clinical trials, the price difference of approximately £124.99-£124.99 monthly means many patients achieve excellent results with Wegovy at the lower cost point, reserving Mounjaro for cases where semaglutide response is inadequate.

When comparing Wegovy vs Mounjaro cost-effectiveness, consider total weight loss goals, your budget for sustained treatment (typically 12-24 months minimum), and individual response. Some patients find the additional efficacy of Mounjaro justifies the higher investment, whilst others prefer Wegovy's proven results at competitive UK pricing. Cured Pharmacy offers transparent upfront pricing before consultation, helping you make informed financial decisions alongside clinical considerations. All prices include UK prescriber assessment, genuine licensed medication, and discreet delivery.

Accessing Treatment Through Cured Pharmacy

Both Wegovy and Mounjaro require prescription-only access in the UK, necessitating clinical assessment by a registered prescriber. At Cured Pharmacy (GPhC 9012511), our online consultation takes under three minutes, reviewing your medical history, current medications, contraindications, and weight loss goals. Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our UK clinical team ensure safe, appropriate prescribing in line with MHRA and NICE guidance. If approved, your medication is dispensed from our registered pharmacy and delivered discreetly to your door, with ongoing support throughout your treatment journey.

Making Your Choice: Wegovy vs Mounjaro Decision Factors

Choosing between Wegovy vs Mounjaro depends on multiple individualised factors beyond simple efficacy comparison. Consider your weight loss target: if you need to lose 15-20% of body weight, Mounjaro's superior trial data may favour this option, whereas 10-15% loss goals are well-served by Wegovy [1][2].

Evaluate your budget for sustained treatment. Weight regain commonly occurs after discontinuation of GLP-1 medications, so selecting a treatment you can afford long-term improves outcomes more than starting with the 'most powerful' option you cannot sustain financially. Wegovy at £124.99 monthly offers proven efficacy at lower cost, whilst Mounjaro at £124.99 provides maximum weight loss potential for those able to commit to the investment [3].

Previous medication experience matters when comparing Wegovy vs Mounjaro. If you have tried liraglutide (Saxenda) with partial success, Wegovy's higher-dose semaglutide often delivers enhanced results. If you have not responded adequately to GLP-1 monotherapy, Mounjaro's dual GIP/GLP-1 mechanism may offer advantages. Discuss your complete medical history, including diabetes status, cardiovascular risk factors, and gastrointestinal sensitivity with your Cured Pharmacy prescriber during assessment.

Both medications represent evidence-based, MHRA-licensed treatments supported by robust clinical trials and real-world data. There is no universally 'better' choice when evaluating Wegovy vs Mounjaro — the optimal treatment aligns your clinical needs, tolerability profile, financial capacity, and personal preferences. Our UK clinical team at Cured Pharmacy provides personalised guidance to help you make the decision that best supports your long-term weight management success, subject to prescriber approval following full assessment.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Cured Pharmacy. (2025). Weight Loss Treatments: Wegovy and Mounjaro Pricing. Retrieved from https://curedpharmacy.com/collections/weight-loss [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.